Why Usana Health Sciences Stock Plummeted This Week
Usana Health Sciences (USNA) shares fell about 30% after its Aug. 4 Q2 results missed expectations and guidance disappointed. The company reported non-GAAP EPS of $0.07 on about $223M sales, with sales and profit below analyst averages. It also took a $29M goodwill impairment on Hiya, cut 2024 guidance to an $11M loss and lowered sales to $910M from $925M-$1B.
How this was made
The 30-second read
Why it matters
The key new driver is the combination of a Q2 miss versus analyst expectations and a guidance reset that now implies a loss for the year, reinforced by a $29M goodwill impairment charge tied to the Hiya business.
Market read
For traders, the actionable takeaway is the guidance and impairment-driven earnings reset, which can sustain volatility until the market sees evidence that headwinds are easing.
What to watch
The article notes weaker Hiya and Rise segments offset stabilization elsewhere, so traders may want to monitor whether those segments show measurable improvement in subsequent quarters rather than extrapolating the full-year cut indefinitely.
Background
USANA reported Q2 results on Aug. 4 and the article attributes the week’s sharp valuation contraction to both the earnings/revenue miss and lowered forward guidance.
Ticker impact
USANA shares fell 30% after its Q2 results missed estimates and it cut full-year sales guidance, alongside a $29M goodwill impairment charge.
Bearish near term, with downside risk until investors see stabilization in Hiya and Rise and confidence returns to full-year guidance.
The disclosed new facts are the Q2 miss, the lowered full-year sales target, and the $29M goodwill impairment that shifts the expected annual outcome toward a loss.
Market effects
Highlights heightened earnings and guidance sensitivity in consumer health and nutrition names when segment headwinds emerge.
Primarily single-name US equity impact; broader indices rose despite the selloff.
Limited direct global spillover beyond investor sentiment toward similar direct-to-consumer health brands.
Counterpoint
If the core nutrition segment is stabilizing, the impairment and guidance cut may be more about accounting and near-term execution than long-term demand collapse.
Key entities
- companyUsana Health Sciences
Subject of the article, with a 30% weekly decline tied to Q2 underperformance, forward guidance disappointment, and a $29M goodwill impairment.
- business_unitHiya business
The segment subject to a $29M goodwill impairment charge, contributing to the guidance and earnings reset.
- business_unitRise segment
Reported as weaker, contributing to the lowered full-year sales guidance.
